Product category review
Is Compounded Semaglutide Safe, and Does It Work?
The honest answer starts with a question almost nobody asks first: is it even the same molecule? According to the FDA, sometimes it is not.
- DifferentWhat the FDA calls the salt forms some compounders use, against the approved drug
- 9 daysDefault beyond-use date for a refrigerated compounded sterile injection
- Not requiredWhether a state-licensed compounding pharmacy must report adverse events to the FDA
- 100+FDA warning letters over compounded GLP-1 marketing since September 2025
The short version
Compounded semaglutide is mixed by a pharmacy rather than manufactured by Novo Nordisk. It has not been through FDA approval, it has not been tested for bioequivalence against the approved drug, and no regulator has verified that what is in the vial matches what is on the label.
That does not automatically make it dangerous, and compounding is a legitimate, long-standing practice. But three specific findings by the FDA should change how you read the marketing: some products do not contain the same active ingredient as the approved drug, dosing errors have put people in hospital, and the adverse event data everyone quotes is structurally incomplete.
Is compounded semaglutide the same as Ozempic?
The approved drugs — Ozempic and Wegovy — contain semaglutide in its base form. The FDA has reported that some compounders instead use salt forms: semaglutide sodium and semaglutide acetate.
What the FDA says
In the FDA’s words these salts are “different active ingredients” from the base form in the approved products. The agency has said it does not have information on whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for using them in compounding.
This matters more than any other point on this page. A product marketed as a cheaper version of Ozempic may not contain the same drug as Ozempic. It is also why the FDA has told sellers to stop describing compounded GLP-1s as “generic” versions of the approved products — there is no generic semaglutide, and a compounded preparation is not one.
You cannot tell from the outside which form you have been sent. A reasonable question for any provider is simply: is this semaglutide base, and can you tell me which pharmacy compounded it? Only a minority of platforms will answer the second part — see our provider comparison.
Compounded semaglutide side effects and safety
The side effects attributed to semaglutide itself — nausea, vomiting, diarrhoea, abdominal pain, constipation — are well documented in the approved product’s labeling and apply here too. What is specific to compounded versions is a different category of risk.
- Dosing errors, some causing hospitalisation. The FDA issued a specific alert about dosing errors with compounded injectable semaglutide, including adverse events it described as serious. The mechanism is mundane and dangerous: compounded vials come in concentrations that differ between pharmacies, so a volume that is correct for one product is an overdose in another. Approved pens are pre-metered; a vial and syringe are not.
- The adverse event count is a floor, not a total. Federal law does not require state-licensed compounding pharmacies to report adverse events to the FDA — only outsourcing facilities have that duty. The FDA itself says events from compounded GLP-1s are therefore likely underreported. Any figure you see quoted, including the ones we have cited elsewhere on this site, undercounts by an unknown margin.
- Nobody has verified the contents. Approved drugs are made under inspected manufacturing controls and tested batch by batch. A compounded preparation carries no equivalent guarantee that potency and purity match the label.
We do not publish dosing information for compounded products. Concentrations vary between pharmacies, which is precisely the reason the FDA’s dosing-error alert exists — a figure that is right for one vial is wrong for another. Follow the instructions from the prescriber who wrote your prescription.
Compounded semaglutide with B12: why it is in there
Many compounded formulations combine semaglutide with cyanocobalamin — vitamin B12. The reason usually given is that B12 helps with the fatigue some people report, or improves tolerability. We could find no trial evidence that adding B12 improves weight outcomes, and no approved GLP-1 product contains it.
There is a regulatory dimension worth understanding. Under the compounding provisions of federal law, a pharmacy generally may not compound a drug that is essentially a copy of a commercially available approved product. Adding an ingredient is one recognised way a preparation can be argued not to be essentially a copy.
Worth knowing
We are not asserting that is why any particular pharmacy adds B12 — we have no evidence of motive. But the FDA has now addressed the practice directly, and it does not accept that adding an ingredient settles the question.
In April 2026 the agency said so explicitly. Restating the conditions a compounded drug must meet, it gave semaglutide combined with vitamin B12 as its worked example: such a product may still be considered essentially a copy of a commercially available drug where the route of administration is the same and the amounts of each ingredient fall within 10% of the approved products’ strengths. It also said it does not intend to act where a compounder fills four or fewer prescriptions of such a product in a calendar month — which is a narrow allowance, not a general permission. If the B12 in your vial was meant to place the formulation outside the copy rule, the FDA’s stated position is that it may well not.
How long compounded semaglutide lasts in the fridge
Compounded sterile injections carry a beyond-use date rather than a manufacturer’s expiry date, and the two are not the same thing. Under the USP standard governing sterile compounding, the default beyond-use date for a refrigerated preparation of this type is nine days. A pharmacy may assign a longer date, but only if it holds stability data supporting it.
In practice, vials are commonly labelled with dates in the range of one to three months. That may be perfectly proper — or it may rest on stability data you have no way to inspect. The date printed on your vial is the only one that governs your product, and it is set by the pharmacy rather than by a regulator.
Storage is refrigerated, 2–8 °C. Almost every page currently ranking for this question is published by a compounding pharmacy or a telehealth platform selling the product, which is worth knowing when you read a generous shelf-life claim.
Compounded semaglutide vs Wegovy and Ozempic
| Compounded semaglutide | Wegovy / Ozempic | |
|---|---|---|
| FDA approved | No | Yes |
| Active ingredient | Base form, or a salt form — varies | Semaglutide base |
| Bioequivalence tested | No | Not applicable — it is the reference product |
| Batch testing for potency and purity | Not guaranteed | Required |
| Dose delivery | Vial and syringe; concentration varies by pharmacy | Pre-metered pen |
| Shelf life | Pharmacy-assigned beyond-use date | Manufacturer expiry date |
| Adverse event reporting to FDA | Not required of state-licensed pharmacies | Required |
| Typical cash cost | Varies widely by platform | $149–$399 a month direct |
The cost column is the one that has changed most. Compounded semaglutide’s original appeal was price during a shortage. With both manufacturers now selling direct at $149 to $449 a month, the saving that justified the trade-off has narrowed considerably.
Where the law is heading
This is the part most product pages omit, and it may matter more than anything else if you are deciding whether to start. In May 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list — the roster of substances outsourcing facilities may legally compound from bulk. If that is finalised, it closes the principal remaining legal route for large-scale compounding of these drugs.
Alongside that, more than a hundred warning letters have gone to compounders and telehealth companies since September 2025 over how these products are marketed. We log each action as it is published, with its primary source, on our regulatory tracker.
Worth knowing
A treatment whose legal basis is under active review is a different proposition from one whose is settled. That is a planning consideration, not a safety claim.
Frequently asked questions
-
Does compounded semaglutide work?
If it contains semaglutide base at the stated potency, there is no reason it would behave differently from the approved drug — the molecule is the molecule. The uncertainty is whether it does, since it has not been bioequivalence tested and some products use a different salt form entirely. No trial has ever tested a compounded version.
-
Is compounded semaglutide safe?
It is not possible to answer that with the confidence the question deserves, and any source that does is overreaching. What is documented: the FDA has recorded dosing errors serious enough to require hospitalisation, has flagged unapproved salt forms, and says adverse events are likely underreported because most compounding pharmacies are not required to report them.
-
Is compounded semaglutide the same as Ozempic?
No, and it is not a generic version of it either — no generic semaglutide exists. It may contain the same active ingredient, or it may contain a salt form the FDA describes as a different active ingredient. Only the compounding pharmacy knows which.
-
How long is compounded semaglutide good for?
Whatever beyond-use date the pharmacy printed on the vial. The USP default for a refrigerated sterile preparation of this kind is nine days; longer dates require the pharmacy to hold supporting stability data. Vials labelled for one to three months are common.
-
Why is there B12 in mine?
The stated reason is usually fatigue or tolerability. No approved GLP-1 contains it and we found no trial evidence it improves weight outcomes. Separately, adding an ingredient can support an argument that a preparation is not “essentially a copy” of an approved drug, which compounding rules restrict.
Sources and method
- Salt forms, and the FDA’s position on them. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. This is also the source for the statement that adverse events from compounded versions are likely underreported.
- Dosing errors and hospitalisations. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.
- Beyond-use dating. The nine-day default for a refrigerated medium-risk sterile preparation comes from the USP standard governing sterile compounding. Individual products may carry longer dates where the pharmacy holds stability data.
- Enforcement record. Logged with primary sources on our regulatory tracker, including the May 2026 503B bulks list proposal and the warning letter waves of September 2025, March 2026 and June 2026.
- What we could not verify. We found no trial evidence on B12 in compounded GLP-1 formulations, and we make no claim about why any pharmacy includes it. We have not independently tested any product. The prevalence of salt-form use is unknown — the FDA reports it occurs, not how often. And because reporting is not mandatory for most compounding pharmacies, no adverse event total for these products can be treated as complete.
What the approved drugs cost → What providers disclose → Regulatory tracker →
Published 27 August 2026. We recheck this page quarterly and whenever the FDA acts on compounded GLP-1s.